JP2021102650A5 - - Google Patents

Download PDF

Info

Publication number
JP2021102650A5
JP2021102650A5 JP2021064764A JP2021064764A JP2021102650A5 JP 2021102650 A5 JP2021102650 A5 JP 2021102650A5 JP 2021064764 A JP2021064764 A JP 2021064764A JP 2021064764 A JP2021064764 A JP 2021064764A JP 2021102650 A5 JP2021102650 A5 JP 2021102650A5
Authority
JP
Japan
Prior art keywords
subject
agonist
administration
composition according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021064764A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021102650A (ja
JP7752373B2 (ja
Filing date
Publication date
Priority claimed from JP2018517270A external-priority patent/JP6940853B2/ja
Application filed filed Critical
Publication of JP2021102650A publication Critical patent/JP2021102650A/ja
Publication of JP2021102650A5 publication Critical patent/JP2021102650A5/ja
Priority to JP2022155051A priority Critical patent/JP2022173426A/ja
Priority to JP2024204921A priority patent/JP2025019234A/ja
Application granted granted Critical
Publication of JP7752373B2 publication Critical patent/JP7752373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021064764A 2015-09-30 2021-04-06 メラノコルチン４受容体経路関連障害を治療する方法 Active JP7752373B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022155051A JP2022173426A (ja) 2015-09-30 2022-09-28 メラノコルチン４受容体経路関連障害を治療する方法
JP2024204921A JP2025019234A (ja) 2015-09-30 2024-11-25 メラノコルチン４受容体経路関連障害を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235003P 2015-09-30 2015-09-30
US62/235,003 2015-09-30
JP2018517270A JP6940853B2 (ja) 2015-09-30 2016-09-29 メラノコルチン４受容体経路関連障害を治療する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018517270A Division JP6940853B2 (ja) 2015-09-30 2016-09-29 メラノコルチン４受容体経路関連障害を治療する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022155051A Division JP2022173426A (ja) 2015-09-30 2022-09-28 メラノコルチン４受容体経路関連障害を治療する方法

Publications (3)

Publication Number Publication Date
JP2021102650A JP2021102650A (ja) 2021-07-15
JP2021102650A5 true JP2021102650A5 (https=) 2021-10-28
JP7752373B2 JP7752373B2 (ja) 2025-10-10

Family

ID=57138146

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2018517270A Active JP6940853B2 (ja) 2015-09-30 2016-09-29 メラノコルチン４受容体経路関連障害を治療する方法
JP2018517274A Active JP7051106B2 (ja) 2015-09-30 2016-09-29 メラノコルチン－４受容体経路関連障害の治療方法
JP2021041611A Pending JP2021088611A (ja) 2015-09-30 2021-03-15 メラノコルチン−４受容体経路関連障害の治療方法
JP2021064764A Active JP7752373B2 (ja) 2015-09-30 2021-04-06 メラノコルチン４受容体経路関連障害を治療する方法
JP2022155051A Pending JP2022173426A (ja) 2015-09-30 2022-09-28 メラノコルチン４受容体経路関連障害を治療する方法
JP2023044399A Withdrawn JP2023078335A (ja) 2015-09-30 2023-03-20 メラノコルチン－４受容体経路関連障害の治療方法
JP2024204921A Pending JP2025019234A (ja) 2015-09-30 2024-11-25 メラノコルチン４受容体経路関連障害を治療する方法
JP2026000058A Pending JP2026042856A (ja) 2015-09-30 2026-01-04 メラノコルチン－４受容体経路関連障害の治療方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2018517270A Active JP6940853B2 (ja) 2015-09-30 2016-09-29 メラノコルチン４受容体経路関連障害を治療する方法
JP2018517274A Active JP7051106B2 (ja) 2015-09-30 2016-09-29 メラノコルチン－４受容体経路関連障害の治療方法
JP2021041611A Pending JP2021088611A (ja) 2015-09-30 2021-03-15 メラノコルチン−４受容体経路関連障害の治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022155051A Pending JP2022173426A (ja) 2015-09-30 2022-09-28 メラノコルチン４受容体経路関連障害を治療する方法
JP2023044399A Withdrawn JP2023078335A (ja) 2015-09-30 2023-03-20 メラノコルチン－４受容体経路関連障害の治療方法
JP2024204921A Pending JP2025019234A (ja) 2015-09-30 2024-11-25 メラノコルチン４受容体経路関連障害を治療する方法
JP2026000058A Pending JP2026042856A (ja) 2015-09-30 2026-01-04 メラノコルチン－４受容体経路関連障害の治療方法

Country Status (20)

Country Link
US (5) US20180215790A1 (https=)
EP (5) EP4360704A3 (https=)
JP (8) JP6940853B2 (https=)
KR (1) KR20180063221A (https=)
CN (2) CN108431023B (https=)
AU (6) AU2016330773A1 (https=)
BR (1) BR112018006674A2 (https=)
CA (2) CA3000673A1 (https=)
DK (1) DK3356386T3 (https=)
ES (1) ES2985734T3 (https=)
FI (1) FI3356386T3 (https=)
HK (1) HK1259424A1 (https=)
IL (3) IL299541A (https=)
MA (2) MA43040A (https=)
MX (2) MX2018003983A (https=)
PL (1) PL3356386T3 (https=)
PT (1) PT3356386T (https=)
SG (1) SG10202101510XA (https=)
WO (2) WO2017059076A1 (https=)
ZA (1) ZA201802704B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
BR112020009648A2 (pt) * 2017-11-15 2020-11-10 Rhythm Pharmaceuticals, Inc. formulações peptídicas de liberação prolongada
CA3090966A1 (en) 2018-02-20 2019-08-29 Charite - Universitatsmedizin Berlin Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
CN108841932B (zh) * 2018-07-13 2021-03-12 东北农业大学 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用
WO2021225972A1 (en) * 2020-05-04 2021-11-11 Regeneron Pharmaceuticals, Inc. Proprotein convertase subtilisin/kexin type 1 (pcsk1) variants and uses thereof
EP4216979A4 (en) * 2020-09-24 2024-11-06 Rhythm Pharmaceuticals, Inc. Methods of treating melanocortin-4 receptor pathway-associated disorders
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4618952A2 (en) * 2022-11-18 2025-09-24 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
WO2024155828A1 (en) * 2023-01-18 2024-07-25 Loma Linda University Health Uses of aminopyridines in the management of weight and satiety
CN118530299B (zh) * 2023-08-25 2025-02-07 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用
WO2026022136A1 (en) * 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1860697A (en) 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
DE10251673A1 (de) 2001-11-09 2003-07-10 Hoffmann La Roche Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
US20060147936A1 (en) 2003-02-19 2006-07-06 Ulrich Frey Use of a gene mutation in the human gnas gene for predicting risks of diseases, courses of the disease and for predicting the response to disease therapies
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
CA2530024A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
PL2286825T3 (pl) 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
EP2106405A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087187A1 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
JP2010516654A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
WO2008087188A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
TW201002340A (en) 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
JP5530438B2 (ja) 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物
US8563742B2 (en) 2008-08-29 2013-10-22 High Point Pharmaceuticals, Llc Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
EP2168965A1 (en) 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
FR2937973B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
JP2012509862A (ja) 2008-11-25 2012-04-26 ノヴォ・ノルディスク・アー／エス 肥満の治療のためのペプチド
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065800A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Hydrazine substituted piperidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
KR101726893B1 (ko) * 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
BR112012002445A2 (pt) 2009-08-05 2015-10-13 Ipsen Pharma Sas uso de um agonista do receptor 4 de melanocortina.
CN102574894A (zh) 2009-08-31 2012-07-11 张力控制股份有限公司 稳定化的黑皮质素配体
US9314509B2 (en) 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
CA2862444A1 (en) * 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
MA43040A (fr) 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4

Similar Documents

Publication Publication Date Title
JP2021102650A5 (https=)
JP2018531937A5 (https=)
Paran et al. Octreotide treatment in patients with severe acute pancreatitis
RU2401841C2 (ru) Лиганды рецепторов меланокортинов
CA2614615A1 (en) Melanocortin receptor ligands
Page Immunologic effects of opioids in the presence or absence of pain
FI3356386T3 (fi) Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
JP2012067099A5 (https=)
US20100221274A1 (en) Method of administering a thymosin alpha 1 peptide
US20100249018A1 (en) Composition and method for preventing and treating immune-related disorder
CN101896190A (zh) 用α胸腺肽和抗细胞毒性T淋巴细胞相关抗原4(CTLA4)的抗体的组合治疗黑素瘤
Holstad et al. A transcriptional inhibitor of TNF-α prevents diabetes induced by multiple low-dose streptozotocin injections in mice
Germain et al. Pulsatile gonadotropin-releasing hormone therapy in persistent amenorrheic weight-recovered anorexia nervosa patients
Murphy et al. Octreotide
AU2002363248A1 (en) Method of administering a Thymosin alpha 1 peptide
Ohnishi et al. Morphine blocks the bradycardia associated with severe hemorrhage in the anesthetized rat
Stewart et al. The future of somatostatin analogue therapy
CN113956334B (zh) 一种棕色脂肪细胞分泌肽及其衍生物在肥胖防治中的应用
RU2025100211A (ru) Способы лечения ожирения агонистом mc4r
JPWO2022067086A5 (https=)
CN105435215A (zh) 重组人钙调磷酸酶b亚基的应用
RU2022132255A (ru) Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4
Carlsen et al. Effects of low-dose glucagon on subcutaneous insulin absorption in pigs
Staykova et al. Infusion of soluble myelin basic protein protects long term against induction of experimental autoimmune encephalomyelitis
Tombal et al. Optimal testosterone control and Eligard®